Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

(2021) Feng-Hua Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

(2020) Shukui Qin et al.   LANCET ONCOLOGY

Relationship of Circulating Tumor Cells and Epstein‐Barr Virus DNA to Progression‐Free Survival and Overall Survival in Metastatic Nasopharyngeal Carcinoma Patients

(2019) Rui You et al.   INTERNATIONAL JOURNAL OF CANCER

Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

(2019) Jia-Wei Lv et al.   Journal for ImmunoTherapy of Cancer

Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma

(2018) Noppadol Larbcharoensub et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

(2018) Jing Huang et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

(2018) Brigette B.Y. Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

(2018) Wenfeng Fang et al.   LANCET ONCOLOGY

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

(2017) Chiun Hsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis

(2016) Federico Rotolo et al.   JNCI-Journal of the National Cancer Institute

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

(2016) Li Zhang et al.   LANCET

Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis

(2016) Federico Rotolo et al.   JNCI-Journal of the National Cancer Institute

The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma

(2015) Li-Ting Liu et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma

(2015) Jianwei Zhang et al.   MEDICAL ONCOLOGY

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis: a retrospective study for the management of treatment

(2013) Yun-Ming Tian et al.   Radiation Oncology